Franklin Genomic Advancements ETF (BATS:HELX – Get Free Report) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totaling 15,981 shares, a growth of 108.6% from the June 15th total of 7,660 shares. Currently, 4.0% of the shares of the stock are short sold. Based on an average trading volume of 4,418 shares, the days-to-cover ratio is presently 3.6 days.
Franklin Genomic Advancements ETF Stock Performance
Shares of HELX opened at $39.49 on Wednesday. The firm has a market cap of $15.80 million, a price-to-earnings ratio of 26.71 and a beta of 1.05. Franklin Genomic Advancements ETF has a fifty-two week low of $26.99 and a fifty-two week high of $41.30. The firm has a 50 day moving average price of $36.34 and a 200-day moving average price of $35.29.
Hedge Funds Weigh In On Franklin Genomic Advancements ETF
A number of large investors have recently added to or reduced their stakes in the business. LPL Financial LLC increased its stake in shares of Franklin Genomic Advancements ETF by 22.4% in the fourth quarter. LPL Financial LLC now owns 11,133 shares of the company’s stock worth $404,000 after buying an additional 2,037 shares during the period. Osaic Holdings Inc. raised its holdings in shares of Franklin Genomic Advancements ETF by 19.1% during the second quarter. Osaic Holdings Inc. now owns 3,132 shares of the company’s stock valued at $87,000 after acquiring an additional 502 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Franklin Genomic Advancements ETF in the 2nd quarter worth about $42,000. Finally, Kestra Advisory Services LLC purchased a new stake in Franklin Genomic Advancements ETF in the fourth quarter worth about $39,000.
About Franklin Genomic Advancements ETF
The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.
Featured Stories
- Five stocks we like better than Franklin Genomic Advancements ETF
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Receive News & Ratings for Franklin Genomic Advancements ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Franklin Genomic Advancements ETF and related companies with MarketBeat.com's FREE daily email newsletter.
